Loading stock data…
$162.03-0.06 (-0.04%)
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally.
Guardant Health, Inc. in the Healthcare sector is trading at $162.03 with a market capitalization of $22.6B. Wall Street consensus targets $201.64 (25 analysts), implying a +24.4% move over the next 12 months. The stock is currently 15% below its 52-week high of $191.05, remaining 27.9% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $334.98M↑ | $301.67M↑ | $281.27M↑ | $265.20M↑ | $232.09M |
| Gross Profit | $219.03M↑ | $196.75M↑ | $181.77M↑ | $171.61M↑ | $150.88M |
| Operating Income | -$129.12M↓ | -$121.35M↓ | -$120.81M↓ | -$98.99M↑ | -$106.41M |
| Net Income | -$120.14M↓ | -$112.08M↑ | -$128.49M↓ | -$92.72M↑ | -$99.90M |
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liqu...